On February 22, 2022 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance after the market closes on Monday, February 28, 2022 (Press release, Supernus, FEB 22, 2022, View Source [SID1234608813]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance on Monday, February 28, 2022 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of financial results, the call will be open for questions.